How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/wild-type-transthyretin-cardiac-amyloidosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Wild-type transthyretin cardiac amyloidosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wild-type transthyretin cardiac amyloidosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Wild-type transthyretin cardiac amyloidosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vyndaqel	Tafamidis Meglumine	Foldrx Pharms	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Vyndaqel	tafamidis	Foldrx Pharms	tafamidis	Transthyretin	2019-01-01
Vyndaqel	tafamidis-test	Foldrx Pharms	tafamidis	Transthyretin	2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Foldrx Pharms · 4 drugs in Wild-type transthyretin cardiac amyloidosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Wild-type transthyretin cardiac amyloidosis:

Cite this brief

Drug Landscape (2026). Wild-type transthyretin cardiac amyloidosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/wild-type-transthyretin-cardiac-amyloidosis. Accessed 2026-06-10.

Wild-type transthyretin cardiac amyloidosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing